Table 1.

Patient characteristics at baseline and start of immunosuppressive therapy

VariablesBaselineImmunosuppressive Therapy
Total CohortConservative TreatmentBaselineStart of Therapy
Patients (n)254130124124
Men (%)686176
Age (yr)53±1451±1455±1356±13
Year of biopsy2003 (1999–2006)2004 (1999–2006)2003 (1998–2007)
Follow-up duration (mo)57 (32–90)53 (31–82)59 (37–103)
Interval until start of therapy (mo)4 (1–13)
BMI (kg/m2)26.3 (23.8–28.8)26.0 (23.7–29.0)26.5 (23.8–28.4)
eGFR-MDRD4 (ml/min per 1.73 m2)71 (53–85)79 (66–89)59 (42–73)41 (31–58)
Serum creatinine (μmol/L)91 (76–116)84 (72–94)109 (86–143)146 (112–181)
Serum albumin (g/L)25 (20–29)28 (23–31)21 (17–27)23 (18–27)
Serum cholesterol (mmol/L)7.2±2.56.6±2.17.9±2.66.8 (5.7–8.4)
Protein-to-creatinine ratio (g/10 mmol)7.1 (4.6–10.7)5.1 (3.2–7.7)10.3 (6.6–12.7)10.4 (7.1–15.2)
Nephrotic syndrome (%)898297
ACE inhibitor/ARB use (%)909090
Statin use (%)626064
Diuretic use726283
Other BP-lowering medication (%)241533
Outcomes (%)
Death8413
Renal replacement therapy315
Serum creatinine > 265 μmol/L11517
Any partial remission during follow-up817984
Any complete remission during follow-up394137
Relapses during follow-up (%)
 0788472
 1191423
 ≥2425
  • Data are presented as mean ± SD, median (interquartile range), and percentages. BMI, body mass index; eGFR-MDRD4, estimated GFR according to the four-variable Modification of Diet in Renal Disease equation, re-expressed for mass spectrometry traceable serum creatinine concentration; ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker.